The goal of this study is to test KM-819 in halting or slowing the progression of Parkinson's disease. The study evaluates the safety and tolerability of multiple ascending doses of KM-819 in healthy older adults and participants with Parkinson's disease.
2 Primary · 28 Secondary · Reporting Duration: Part 1a and Part 1b: From screening (Day -42 to -3) up to 7 days and Part 2: From screening (Day -42 to -2) to 730 days
Experimental Treatment
330 Total Participants · 8 Treatment Groups
Primary Treatment: Part 1a: Cohort 1.1a Dose 400 mg · Has Placebo Group · Phase 2
Age 18+ · All Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: